Health Canada approves $2.8M treatment for spinal muscular atrophy

Health Canada has approved Zolgensma, which is bringing renewed hope to Alberta families that have been tirelessly fundraising to afford its staggering cost of $2.8 million.

At least four children in Alberta have been diagnosed with the rare and debilitating disease spinal muscular atrophy (SMA).